Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Court Rules Natco CL Of Bayer Drug Does Not Extend To Exports

This article was originally published in PharmAsia News

Executive Summary

The Delhi High Court ruled the India government's grant of a compulsory license for Natco Pharma to market a generic of Bayer's Nexavar (sorafenib) for treating kidney and liver cancers did not carry a right to export it.

You may also be interested in...



Novartis’s Beovu Launch Clouded By Safety Worries

New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.

Neuraxpharm Buys Glenmark’s Polish CNS Assets

Neuraxpharm has struck a deal to acquire Glenmark’s CNS portfolio in Poland. As part of the agreement, Glenmark’s Jacek Sawicki has been named as general manager of Neuraxpharm Polska and will lead a business that now incorporates Glenmark’s CNS commercial team.

Cardiovascular Sales & Earnings Round-Up: Medtronic TAVR Disappoints While Abbott And Boston Scientific See Structural Success In 2019

The top five cardiovascular device companies, as ranked by Medtech Insight’s MTI 100, have reported their sales and earnings for the last quarter of the calendar year 2019. Here are the highlights from the most recent presentations from Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences and Terumo.

Topics

UsernamePublicRestriction

Register

SC086645

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel